NEWS & COMMENT

capture at least 10% of this market.

Corvas assigned a team to the project, although the two groups had no intellectual property rights agreement. Both sides do agree Corvas advanced the work, allowing researchers to begin to sequence the protein and identify two others. But chinks in the relationship began to appear by 1994. Corvas had asked Yale for the license to the AcAP patent, but the university—unimpressed with the company's offer—instead sold the license to Biomedisyn, a start-up biotechnology firm near New Haven, Connecticut. Biomedisyn's founder, Frank Volvovitz (former president of vaccine-maker MicroGeneSys) was very interested in vaccines.

Corvas continued largely on its own to perform extensive tests, including full protein sequencing, cloning, and testing in animals. A company press release in December noted that at a recent conference, Corvas scientists presented "promising preclinical results on its proprietary" AcAP proteins, which it has renamed NAP, for nematode anticoagulant proteins. Kabakoff says he's confident that the company's claims—when made public at the end of the patent process—will withstand scrutiny.

Volvovitz is unconvinced. "Anytime anyone wants to ignore a patent someone has, they can come up with all kinds of reasons," he says. Volvovitz, like Yale and Corvas officials, says he holds out hope for an amicable agreement. What may make it difficult is that any profits Corvas might make from an anticoagulant could undercut Biomedisyn's attempts to use sales of a similar drug to fund vaccine work. So, says Volvovitz, "we do have some concerns over what Corvas has done so far."

This bicoastal biotech wrangling may be a harbinger of industry-academia struggles to come. The Association of University Technology Managers found in a survey last year that the number of new technology license and option agreements between industry and academia has increased 63% from 1991 to 1994, to 2484. Purdue's Willey says most of these fare much better than the Yale-Corvas deal did. Still, a survey of 210 biotechnology company executives published in the 8 February *New England Journal of Medicine* found that 34% had "disputes with their academic partners over intellectual property." Joyce Brinton, director of Harvard University's Office of Technology and Trademark Licensing, says the hookworm affair highlights the need for collaborators to make their full intentions known at the outset of the relationship. "Since the interests are different," she says, "it might be helpful if everyone talked out what everybody's objectives are."

Brinton warns, however, that caution taken to extremes could actually stifle research. "Yes, you need to make sure you've got i's dotted and t's crossed. But the last thing a scientist wants is for someone to come with 16 pages of contracts to sign."

–Jock Friedly

Jock Friedly is a free-lance writer in Arlington, Virginia.

___AFFIRMATIVE ACTION_

Diversity Takes a Student Body Blow

A larms rang on campuses across the United States last week after a court ruled that the University of Texas (UT) law school's admissions policies violated the U.S. Constitution's guarantee of equal protection under the law by giving preference to blacks and Hispanics over whites. The ruling could dismantle programs to improve minority admissions rates at U.S. professional schools. And while its effects on science graduate programs are likely to be more muted and less direct, observers say they could still be profound.

The ruling in Hopwood v. Texas by the 5th U.S. Circuit Court of Appeals in New Orleans now applies only to Texas, Louisiana, and Mississippi, and UT is currently deciding whether to appeal it. If the decision is upheld by the U.S. Supreme Court, it "would render unconstitutional the admissions policies of virtually every public institution in America," says University of Virginia law professor John Jeffries.

Science graduate programs themselves are not directly in the line of judicial fire. Microbiologist John Alderete of the UT Health Science Center in San Antonio says the ruling wouldn't affect his department because there are no policies that distinguish applicants based on race or ethnicity. Chemist Billy Joe Evans of the University of Michigan, Ann Arbor, says the procedures for admission to graduate departments tend to be sufficiently informal that "we can do pretty much what we want to do." Law and medical school admissions, in contrast, rely more heavily on national standardized tests, which can be weighted to favor minority applicants. Indeed, in an analysis last year, the Association of American Medical Colleges (AAMC) found that if admissions were based solely on grades and test scores, "(with the exception of Asians) the complexion of selective higher education institutions, including medical schools, would return to that of the 1950s" (Journal of the American Medical Association, 21 February 1995).

Where science education would feel the impact—if the Supreme Court extends the ruling nationwide—is at the undergraduate level. "If you could not consider race at all ... [there would be] an extremely drastic decline in the enrollment of disadvantaged minorities," says Gary Orfield, professor of education and social policy at Harvard University. And that would give grad programs even fewer minority students to choose from. The effect would be "horrible," says Herbert Nickens, vice president for community and



Less diversity? The policy that admitted these students to the University of Texas can't take race into account.

SCIENCE • VOL. 271 • 29 MARCH 1996

minority programs of the AAMC.

Engineer Carl Pister, chancellor of the University of California (UC), Santa Cruz, says the UC system is already seeing results from the UC Regents' decision last summer outlawing race-based admissions. Even though the order doesn't go into effect until next year, he says, applications by underrepresented minorities appear to be down about 10% in anticipation. And admissions aren't the only programs touched by the ruling. Race-based scholarship programs could be in jeopardy, says the lawyer for the plaintiffs, Michael Greve of the Center for Individual Rights in Washington, D.C. And while recruitment programs would not be directly affected, says Pister, more care would have to be exercised to be sure they weren't exclusionary. That's already happening in California, he says: Outreach programs such as MESA (Mathematics, Engineering, and Science Achievement) are structured to be open to members of all racial and ethnic

categories, although they are designed to attract minority candidates in particular.

Whatever the final disposition of this case, there seems to be agreement in most quarters that it is part of a larger trend (see p. 1908). Says National Science Foundation general counsel Larry Rudolph: "I think this is clearly going to be one of the more difficult and challenging issues of the next decade ... [trying to increase minority representation in education] while still being able to pass constitutional muster." –Constance Holden